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INCREASED INTRAOCULAR PRESSURE IS
A RISK FACTOR FOR UNEXPLAINED
VISUAL LOSS DURING SILICONE OIL
ENDOTAMPONADE
MARVIN MARTI, MD,* RICHARD WALTON, MSC,† CHRISTIAN BÖNI, MD,*
SANDRINE A. ZWEIFEL, MD,* MARC STAHEL, MD,* DANIEL BARTHELMES, MD, PHD*†
Purpose: To identify the incidence rate and risk factors for unexplained visual loss
associated with silicone oil endotamponade used during primary repair of macula-sparing
rhegmatogenous retinal detachments.
Methods: This retrospective cohort study included patients undergoing pars plana vitrectomy
for primary surgical repair of macula-sparing rhegmatogenous retinal detachments in whom
silicone oil endotamponade was used. The primary outcome measure was the incidence rate of
unexplained visual loss and identiﬁcation of risk factors associated with vision loss.
Results: Of 1,218 eyes undergoing pars plana vitrectomy for primary retinal detachment
repair, 44 eyes were included for analysis. In 9 eyes (20%), an unexplained vision loss
occurred. Logistic regression identiﬁed increased intraocular pressure (IOP) (prospectively
deﬁned as IOP readings during silicone oil endotamponade$21 mmHg on two consecutive
visits or $25 mmHg at any time during this period) as signiﬁcant predictor (odds ratio = 4.9;
P = 0.04) and a classiﬁcation tree ranked IOP as the most important variable for vision loss.
Incidence rate of vision loss in eyes experiencing IOP increase was 4.5 vision loss events
per 1,000 days at risk compared with 1 event per 1,000 days in eyes without IOP increase,
yielding an incidence rate ratio of 4.5 (95% conﬁdence interval: 1.1–17.9; P = 0.02).
Conclusion: Sufﬁcient control of IOP during silicone oil endotamponade for primary
retinal detachment repair is warranted to reduce the probability of vision loss.
RETINA 0:1–7, 2017
Today, many rhegmatogenous retinal detachments(RRDs) are treated by pars plana vitrectomy
(PPV) and gas endotamponade. In some cases such
as with associated proliferative vitreoretinopathy
(PVR), giant retinal tears (GRT), inferior tear loca-
tion, or redetachments, silicone oil (SO) is used for an
adequate endotamponade.1–3 Known complications
of SO endotamponades are cataract formation, band
keratopathy, glaucoma, and SO emulsiﬁcation,4,5
although newer formulations seem to carry lower
risks of emulsiﬁcation.6
Recently, attention has been directed to another
severe SO-related complication that is now reported
more and more frequently. A considerable proportion
of eyes treated with SO endotamponade for macula-
sparing RRDs suffer from a profound unexplained
visual loss.7,8 Recent studies report on incidence rates
(IRs) of nearly 30%.7,8 So far, the only associated risk
factor identiﬁed was the duration of SO ﬁlling.7
The aim of this study was to identify the IR, risk
factors, and time of occurrence of unexplained visual
loss in patients with SO endotamponade.
Methods
Ethics
Ethics Committee approval was obtained from the
Local Ethics Committee of the Canton of Zurich. The
study adheres to the tenets of the Declaration of Helsinki.
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Patient Data
A retrospective analysis was performed on all eyes
that underwent 23-g PPV from 2012 to 2014 at the
University Hospital of Zurich. Included were eyes
undergoing PPV for macula-sparing retinal detach-
ments with primary SO endotamponade. Exclusion
criteria were eyes with macula-involving retinal
detachments, redetachments, non-RRDs, and presence
of signiﬁcant vision-inﬂicting comorbidities (i.e.,
macular pathologies or anterior segment pathologies),
additional buckling surgery, or additional lens-related
surgery (lentectomy/phacoemulsiﬁcation/intraocular
lens implantation) during primary PPV.
Preoperative data included age, sex, visual acuity
within 24 hours before RRD repair during preopera-
tive examination, presence of GRT, lens status,
refractive error (spherical equivalent), type of SO
used, and presence and grade of PVR.
Postoperatively (both after initial RRD repair with
SO ﬁlling and after PPV for SO removal), all patients
were seen on the ﬁrst day after surgery, weekly during
the ﬁrst month and after 1, 2, and 3 months. During
each visit (preoperatively and postoperatively), best
visual acuity achieved using either glasses and/or
pinhole was measured with Snellen charts and trans-
formed to the logarithm of the minimum angle of
resolution (logMAR) for statistical analysis. Besides
visual acuity, at every visit, intraocular pressure (IOP)
and status of the retina were examined. This reﬂects
postoperative routine care for all patients treated at the
surgical retina department and allows for a detailed
review of the development of vision, IOP, and potential
complications during the postoperative period. Intra-
ocular pressure was prospectively deﬁned as increased
if IOP readings during SO endotamponade were $21
mmHg on two consecutive visits, and if IOP was $25
mmHg at any time during this period.
For all patients, duration of SO endotamponade was
calculated. In all patients with a vision loss, optical
coherence tomography examination was performed to
rule out secondary causes for visual loss (e.g., macular
edema, signiﬁcant epiretinal membrane, and persistent
subretinal ﬂuid). Where necessary, a ﬂuorescence
angiography was obtained to rule out retinal vascular
occlusion. Vision loss was deﬁned as a loss of two or
more Snellen lines from baseline visual acuity before
RRD repair compared with best-corrected vision after
SO removal, with no evident explanation.7,9
Outcome Measures
The primary outcome measure was the IR of
unexplained visual loss and identiﬁcation of risk factors
associated with vision loss. Secondary outcome meas-
ures were time to vision loss, duration of SO endo-
tamponade, and visual acuity and IOP changes.
Statistics
Summary statistics include mean or median and SD
or interquartile range (IQR) where appropriate.
Exploratory analyses were undertaken with Bayesian
logistic regression and classiﬁcation trees. Candidate
risk factors were then used to compute the IR ratio to
quantify the relative risks.
All analyses were performed with R version 3.1.3
using the ARM and Rpart packages.
Results
Patients
From 2012 to 2014, a total of 1,218 eyes underwent
PPV to treat retinal detachments (Figure 1).
In 248 (20.4%) eyes, SO endotamponade was
needed because of the presence of GRT, inferior tear
location, and signiﬁcant PVR. Macula-involving RRDs
were seen in 167 eyes; in 13 eyes, a redetachment was
present after previous surgeries were performed else-
where. In nine eyes, SO was used in the treatment of
primary retinal detachments in the setting of endoph-
thalmitis (n = 2), acute retinal necrosis (n = 2), exten-
sive peripheral tractional retinal detachment due to
toxoplasmosis (n = 1), traumatic detachment (n = 1),
peripheral traction detachment secondary to tuberculo-
sis (n = 1), congenital glaucoma surgery (n = 1), and
neovascular age-related macular degeneration with
extensive subretinal exudation and hemorrhage
(n = 1). Overall, 59 primary macula-on RRDs were
treated with SO endotamponade. After exclusion of 6
eyes, which were lost to follow-up (tourists who
needed to ﬂy back home), and 9 eyes with an explained
visual loss (macula-involving redetachment under SO
endotamponade in Stickler syndrome n = 5, intraoper-
ative macular damage n = 1, dense cataract n = 1, and
toxic macular damage n = 1), a total of 44 patients
remained for ﬁnal analysis (Figure 1). None of the
patients with an unexplained visual loss showed mac-
ular edema or a thinning of the central retina on optical
coherence tomography cross-sections.
As stated, all patients were followed-up routinely on
the ﬁrst day after the operation, weekly during the ﬁrst
month and after 1, 2, and 3 months allowing for
a detailed documentation of the course of IOP and
visual acuity. Characteristics of eyes with and without
unexplained visual loss are shown in Table 1.
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Primary Outcome Measures
An unexplained visual loss was found in 9 of 44
patients (20%, Figure 2). Initial exploratory analyses
identiﬁed increased IOP as a clear safety signal.
Among eyes with recorded increased IOP, median
time to increased IOP, as deﬁned above, was 10.2
days [IQR: 1–14 days]. The IR of vision loss in eyes
experiencing IOP increase was 4.5 vision loss events
Fig. 1. Flowchart for identiﬁ-
cation of eligible eyes for ﬁnal
analysis.
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per 1,000 days at risk (6/1,334) compared with 1
event per 1,000 days (3/2,993) in the other eyes
(i.e., without IOP increase) yielding an IR ratio of
4.5 (95% conﬁdence interval: 1.1–17.9; P = 0.020).
Thirty-eight percent (6/16) of eyes with increased IOP
experienced visual loss compared with 10.7% (3/28)
of the remaining eyes. Logistic regression identiﬁed
IOP as the most important predictor (odds ratio = 4.9;
P = 0.044), and a classiﬁcation tree ranked IOP as the
most important variable.
Secondary Outcome
Comparison of eyes with and without visual loss
showed no evident differences regarding age, sex,
refractive error, rate of GRT, and presence and grade
of PVR.
Median visual acuity dropped from 20/25 (logMAR
0.1, IQR: 0.1–0.1) preoperatively to 20/125 (logMAR
0.8, IQR: 0.7–1.3) (P , 0.001) in the unexplained
vision loss group. In eyes without visual loss, vision
remained stable at 20/32 (logMAR 0.2, IQR: 0.1–0.4)
preoperatively to 20/32 (logMAR 0.2, IQR: 0–0.3)
postoperatively.
Preoperative visual acuity in the group without vision
loss was lower due to 3 patients with vitreous
hemorrhage. In all patients, vision loss occurred during
SO endotamponade, documented during regular clinical
follow-up. Median vision loss occurred at 108 days
(IQR: 60–120 days) days after SO endotamponade.
Mean duration of SO ﬁlling in the group with vision
loss was 161.0 ± 38.8 days and signiﬁcantly longer as
compared with 104.6 ± 43.6 days (P , 0.001) in eyes
without vision loss. Mean maximal IOP in eyes with
vision loss was 26 ± 9 mmHg, whereas in eyes without
vision loss, the mean maximal IOP was only 21 ± 7
mmHg (P = 0.1).
Discussion
This study in primary macula-on RRDs requiring
SO endotamponade found an IR of an unexplained
visual loss of 20.5% and increased IOP during SO
endotamponade as the most important risk factor to
develop vision loss. Furthermore, all events of vision
loss were found to occur during SO endotamponade.
The most relevant risk factor for developing
unexplained visual loss was an increased IOP during
SO endotamponade: events of increased IOP were
observed more often in eyes developing vision loss.
Although the duration of SO endotamponade was
longer in eyes with vision loss, regression analysis did
not identify duration of SO endotamponade as a risk
factor—which is in contrast to a recent study, where
duration of SO endotamponade was associated with
an unexplained visual loss.7 Other variables such as
age, sex, lens status, degree of myopia, signiﬁcant
PVR, and presence of GRT were not associated with
vision loss.
Until now, the only risk factor described is duration
of SO endotamponade.7 The authors, who presented
data on 11 patients with an unexplained visual loss,
did not ﬁnd an effect of IOP elevation. In contrast to
the current analysis, they compared the median of the
highest IOP during SO tamponade of affected (vision
loss) and unaffected eyes. Taking a closer look at the
data shows that 8 of 11 (73%) affected patients
showed IOP spikes exceeding 25 mmHg supporting
our ﬁnding that IOP elevations are related to unex-
plained visual loss. It may be possible that not only
the highest IOP is relevant for developing unex-
plained visual loss but also an increased IOP during
a certain period.
Many studies describe vision loss to occur during
SO endotamponade or after SO removal,7–9 others re-
ported that vision loss developed during SO endotam-
ponade.10 In all our patients, vision loss occurred
during SO endotamponade. Because of the established
postoperative follow-up routine, including control of
visual acuity with correction of the refractive change
through SO by adding lenses and/or by using a pinhole,
we were able to identify the time point of visual loss.
In contrast to the actual time of the vision loss, most
Table 1. Overview of Demographics and Ocular Findings
Before PPV
No Vision Loss Vision Loss P
N 35 9
Age, mean (SD) 57.2 (10.87) 54.8 (6.42) 0.532
Sex, % 1.0
Female 7 (20) 2 (22.5)
Male 28 (80) 8 (77.5)
Myopia, % 0.1
0 to 23 dpt 20 (57.15) 4 (44.5)
23 to 26 dpt 8 (22.85) 5 (55.5)
More than 26 dpt 7 (20)
Pseudophakia, % 1.0
Yes 10 (28.5) 2 (22.2)
No 25 (71.5) 7 (78.8)
GRT 13 (36.1) 2 (22.5) 0.695
PVR, % 0.575
No PVR 15 (42.9) 6 (66.7)
Grade A 4 (11.4) 1 (11.1)
Grade B 11 (31.4) 1 (11.1)
Grade C 5 (14.3) 1 (11.1)
SO type, % 0.712
1,000 ct 13 (37) 3 (33.33)
1,300 ct 20 (57) 6 (66.66)
5,000 ct 2 (6)
ct, centistokes; dpt, diopters of spherical equivalent.
4 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES  2017  VOLUME 0  NUMBER 0
Copyright ª by Ophthalmic Communications Society, Inc. Unauthorized reproduction of this article is prohibited.
patients only realized the vision loss after SO removal
and after resorption of the gas or air bubble instilled
during SO removal. Because visual acuity under SO
endotamponade may not regularly be examined in rou-
tine practice, and not all patients may realize decreased
vision until after removal of SO, it is very well possi-
ble that in previous studies an actual vision loss during
SO tamponade was mistaken for a vision loss after SO
removal. We suggest—in line with previous reports—
that unexplained vision loss rather occurs during SO
endotamponade.10
We found a strong relationship between vision loss
and IOP elevation. Intraocular pressure increase
always preceded vision loss, which occurred during
SO endotamponade and not after SO removal. We
believe that insufﬁcient pressure control under SO
endotamponade plays a key role in the pathogenesis of
unexplained visual loss. Nevertheless, how does an
increase in IOP lead to a selective central vision loss,
and why do only certain patients with IOP problems
experience such a vision loss?
Only recently, a study found a focal severe retinal
nerve ﬁber layer (RNFL) loss of the papillofoveal
projection and microcystic macular changes in the inner
nuclear layer as pathomorphological correlate suiting
the severe central vision loss.11 All patients were men-
tioned to have had an increased IOP. As SO has been
shown to inﬁltrate various parts of the eye, such as the
anterior chamber angle, iris, ciliary body, retina, prere-
tinal and subretinal membranes as well as the optic
nerve, and even up to the lateral ventricles,12,13 the
microcystic changes were discussed to be emulsiﬁed
oil droplets.11 However, as the RNFL loss precedes
the appearance of the vacuoles and the vacuoles are only
located in the inner nuclear layer, this was considered
unlikely. The described microcystic changes in the inner
nuclear layer together with an RNFL thinning were pre-
viously shown in optic nerve diseases such as multiple
sclerosis,14–18 neuromyelitis optica,19–21 idiopathic optic
atrophy,15 relapsing isolated optic neuritis,16 compre-
hensive neuropathy,22 hereditary optic neuropathy,16,23
trauma,16 and Tanzanian endemic optic neuropathy.
Fig. 2. Events of vision loss are
depicted as a red dot and events
of increased IOP are a yellow
dot. All instances of increased
IOP occurred between 1 and 30
days. Instances of vision loss
occurred between 30 and 120
days. Thirty-eight percent (6/16)
of eyes with increased IOP
experienced visual loss. All in-
stances of increased IOP pre-
ceded associated instances of
vision loss. Black lines visualize
time in days since SO
endotamponade.
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Furthermore, they have been shown in eyes with glau-
coma.24 Patients with advanced stages of glaucoma
were more frequently affected and showed a worse
mean defect slope of visual ﬁeld suggesting a relation-
ship with insufﬁcient pressure control. The microcystic
changes were discussed to occur rather with a localized
RNFL thinning, as very severely affected eyes with
a mean defect , 215.3 dB and thus a widespread
RNFL loss did not show any microcysts. Different path-
ogenetic mechanisms for the development of microcys-
tic changes in eyes with optic neuropathies and in eyes
with glaucoma have been discussed. For optic neurop-
athies, the most popular is the theory of retrograde trans-
synaptic degeneration,25 which is a subject of debate
though.23 Inﬂammatory processes,14 Müller cell dys-
function,18 or vitreomacular traction were discussed23
as alternative possibilities. For glaucoma patients, who
were suggested to have rather localized RNFL defects,
at least in part, a mechanical traction was suggested. In
patients with unexplained visual loss, the retinal
changes were shown to occur localized as well, affect-
ing primarily the papillomacular bundle11 and leading to
a central visual ﬁeld defect shown in microperimetry.7
In consideration of these ﬁndings and the clear associ-
ation with IOP problems in our study, a mechanical
damage of the nerve ﬁbers under changed biomechanics
of the eye after vitrectomy and under SO endotampo-
nade with a consecutive development of microcysts in
the inner nuclear layer could be hypothesized. A
perfusion-related damage might be an alternate expla-
nation. Pressure spikes may reduce the ocular perfusion
pressure leading to a speciﬁc damage of highly meta-
bolically active nerve ﬁbers in the papillomacular
bundle, which are known to have particularly high aden-
osine triphosphate (ATP) requirements.26,27 Further-
more, a mitochondrial insufﬁciency, as seen in
patients with endemic optic neuropathies, could play
a vital role,27 especially in conjunction with IOP eleva-
tions. Mitochondrial insufﬁciency may lead to cell
injury and death if compensatory mechanisms like pro-
liferation of mitochondria and axonal transport to the
site where ATP production is needed fail.27 Axoplasmic
transport is more energy demanding; the smaller the
caliber, the less myelinated the ﬁbers are. Delay in the
axonal transport was proposed to lead to a breakdown of
the transport system resulting in cell death. Very long
and ﬁne, constantly ﬁring ﬁbers with a high metabolic
demand, as in the optic nerve, have been shown to be
most vulnerable. In patients with SO ﬁlling, there are
changes in the metabolism, like for instance, elevated
potassium levels28 and changes in the level of cyto-
kines29 have been described. A resulting mitochondrial
insufﬁciency with damage of the vulnerable ﬁbers in the
RNFL of the papillomacular bundle in conjunction with
a hindered axoplasmic transport under an elevated IOP
is a possible pathogenetic mechanism in the develop-
ment of unexplained visual loss.
Main strengths of this analysis are the large sample
size, the formal risk analysis of visual loss related to
SO endotamponade, and the uniform dataset from
postoperative follow-up examinations. Visual acuity
and IOP were measured at given intervals, and visual
acuity was measured using correction.
The limitations of the study are inherent to the
retrospective nature, especially lack of a control
group where IOP was controlled to remain within
normal ranges.
Given the robust dataset and the ﬁndings that are in
line with previous reports, patients should be advised
of visual loss despite a preoperatively attached macula
situation and IOP elevations should be treated. As in
all of our affected patients, IOP elevations occurred
before detection of visual loss, we suppose insufﬁ-
cient IOP control plays a key role in the pathogenesis
of unexplained visual loss. The pathophysiology
remains unclear. Because of the strong association
with IOP elevations, we implemented a strict post-
operative pressure management into clinical routine
and found that the incidence has markedly dropped
since. In 2015 and 2016, no case of unexplained
visual loss has occurred at our clinic.
Key words: vision loss, silicone oil, silicone endo-
tamponade, vitrectomy, pars plana vitrectomy.
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